Previous Page
11-06/07 :: June/July 2011
nanotimes
Companies Facts
the year-ago period. License and research revenues were $2.5 million versus $3.3 million in the second quarter of 2010. Product sales and services in the current quarter increased to $2.3 million versus $1.9 million in the second quarter of 2010. Other reve- nues during the current quarter, including royalties on the sale of Coreg CR™, were $2.0 million versus $2.4 million in the year-ago period.
from sunlight, enabling the production of superior Selective Emitter solar cells. According to industry es- timates, Selective Emitter technology could represent 13 percent of crystalline silicon solar cell production by 2013 and up to 38 percent by 2020.
Image: Silicon inks from DuPont Innovalight boost the amount of electricity produced from sunlight, enabling the production of superior Selective Emitter solar cells. © Dupont/Innovalight
yesol Ltd. announced the issuance of 2,076,843 ordinary fully paid shares at AUD 0.3852 per
share. The shares have been issued upon conversion of a convertible security.
lamel Technologies S.A. (NASDAQ: FLML) reported total revenues in the second quarter 2011 of $6.8 million, compared to $7.5 million in
Furthermore, Flamel Technologies SA and Digna Biotech SL announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products. The agreement has been structured to leverage Digna’s groundbreaking research, preclinical and clinical development efforts, and Flamel’s for- mulation expertise in creating safer, more efficacious products using its innovative proprietary drug delive- ry platforms, Medusa®
and Micropump® .
Flamel will be primarily responsible for the formu- lation and manufacturing process development and
Costs and expenses during the second quarter of 2011 were $(10.4) million versus $(12.2) million in the year-ago period. Costs of goods and services sold in the quarter totaled $(1.9) million versus $(1.6) million in the second quarter of 2010. Research and development expenses were $(5.9) million versus $(7.9) million in the second quarter of 2010. SG&A declined to $(2.5) million from $(2.8) million in the year-ago period. Net loss in the second quarter of 2011 was $(3.5) million, compared to a net loss of $(4.3) million in the second quarter of 2010. Net loss per share (basic) for the second quarter of 2011 was ($0.14), compared to a net loss per share (basic) in the year-ago period of ($0.18).
31